[Solutions for Evaluation of CAR Expression] Fluorescence-labeled Proteins, Biotinylated Proteins, Unconjugated Proteins_ACROBiosystems 한국 수입공급 전문 - 코아사이언스

안녕하세요!

표적 치료제, 진단, 백신 연구관련 시약 및 재조합단백질 전문 제조사 ACROBiosystems 공식 수입/공급 업체 코아사이언스 입니다.

 

자세한 상품 정보 및 관련 문의는 전화 02-858-0328 또는 info@coresciences.co.kr로 문의주시기 바랍니다.

감사합니다!

 

Fluorescence-labeled Proteins

PE-labeled

Her2      CD4     Anti-FMC63 Ab     BCMA      CD19     MSLN     CD33    CLL-1     SLAMF7    CD30    CD7    EGF R      EGFRvIII      GPC3       GUCY2C      ROR1

 

FITC-labeled

Anti-FMC63 Ab     BCMA      CD123    CD138    CD19    CD22     CD30    CD38    CD4     CD70    CD5   CD8A & CD8B     CLL-1     EGF R     EGFRvIII     FAP     FOLR1     GPC3      GUCY2C    Her2     Her3     IL13RA2     MSLN   PSMA   ROR1   SLAMF7   CD56   B7-H3   EpCAM  CD147   IL-13 R alpha 2   CD7   Nectin-4

 

Biotinylated Proteins

Anti-FMC63 Ab    B7-H3    BCMA    CD138    CD147    CD19    CD22    CD30    CD33    CD38    CD4    CD70    CEA    EGF R    EGFRVIII    EpCAM    FAP    FOLR1    GPC3    Her2    Her3    HGFR    MSLN    MUC16   Nectin-4    PSMA    ROR1    SLAMF7    uPAR     VEGFR2      CD56    CD7     CD5     IL-13 R alpha 2

 

Unconjugated Proteins

Anti-FMC63 Ab    B7-H3     BCMA     CAIX    CD123     CD133    CD138    CD147    CD19    CD22     CD30     CD33     CD38     CD4     CD7     CD70    CEA    EGF R     EGFRVIII    FAP    EpCAM    FOLR1    GPC3    Her2    Her3     HGFR     IL13RA2    MSLN     MUC1     Nectin-4      NKG2D     PSCA     PSMA     ROR1      SLAMF7     uPAR    VEGFR2

 

The chimeric antigen receptor T (CAR-T) cell therapy is a new treatment for a variety of cancers. The idea is to take the T-cells from the patient, and genetically engineer the cells to express a chimeric antigen receptor (CAR) which recognizes a specific tumor-associated antigen (TAAs). As a result, the CAR-expressing T cells, when reintroduced into the patient's body, will target and eliminate the TAA-expressing tumor cells.

Evaluating CAR expression is an essential step in the production of CAR-T cells. This is often done by flow cytometry, using protein L, anti-Fab antibodies or target antigens as detection methods. Among these common choices, target antigens are widely considered to be the best option, because it offers high specificity and minimal background staining.

ACROBiosystems has developed an extensive collection of recombinant proteins to support CAR-T therapy development. This growing list of proteins includes many fluorescent-labeled target antigens and pre-biotinylated proteins that are uniquely suitable for evaluation of CAR expression. In addition, we also supply difficult-to-express proteins such as BCMA, CD19, ROR1, and EGFRVIII.

 

추천 상품 

[가스 투과성 세포 배양 백] NIPRO Cell Culture Bags [87-352, 87-302] & Connecting Tube [87-360]

[마이크로플레이트 웰에서 효과적인 세포 회수/소형 셀 스크래퍼] Mini Cell Scraper: Best size for 24, 48 and 96 well culture plates [MCS-200]

 

미니 셀 스트래이너/미니 셀 스트레이너/Single cell 분리] Mini Cell Strainers for 5 ml sampling tubes and 15 ml conical tubes [HT-AMS-12502, HT-AMS-14002, HT-AMS-17002] & Mini Cell Strainer II for 1.5 mL/2.0 mL tube and 5 ml sampling tubes [HT-AMS-04002, HT-AMS-04008]

코아사이언스 coresciences Acrobiosystems Acro biosystems 면역치료제 immuno cell therapy targeted therapy cytokines 사이토카인 recombinant proteins 재조합 단백질 인터페론 CART T cell B-cell natural killer cell 자연살상세포 항체 antibody 면역학 immunology